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Case presentation
A 41-year-old black man was admitted to the Massachusetts General
Hospital (MGH) because of shortness of breath. The patient had been
hypertensive for 10 years. and had been treated with propranolol, 40mg
orally three times daily. On the day of admission, he became acutely
short of breath, but he denied chest pain and other cardiovascular
symptoms. Blood pressure at the time of admission was 200/100 mm
Hg. His bean rate was 150 beats/mm, and the electrocardiogram
revealed global ST-segment and T-wave changes consistent with diffuse
myocardial ischemia. Measurement of blood gases obtained while the
patient was breathing room air revealed a Pa02 of 64 mm Hg, PaCO2 of
91 mm Hg. and pH of 7.05. Physical examination disclosed rales in both
lung fields to the apices; the chest x-ray revealed bilateral alveolar
pulmonary edema. The patient was intubated and given 100% oxygen.
His blood pressure fell to 120/70mm Hg and his heart rate decreased to
50 beats/mm. A second electrocardiogram revealed complete heart
block and acute right bundle-branch block. Treatment with intravenous
epinephrine. atropine, morphine sulfate, and furosemide resulted in an
improvement in pulmonary function, resumption of sinus rhythm, and a
prompt diuresis. The blood pressure rose to 200/120 mm Hg, and the
heart rate increased to 110 beats/mi Funduscopic examination re-
vealed arteriolar narrowing but no hemorrhages or exudates. Examina-
tion of the chest revealed normal breath sounds bilaterally; no rales or
rhonchi were present. Cardiac examination revealed normal first and
second heart sounds; a loud summation gallop was heard, but there
were no murmurs, rubs, heaves, or thrills. The point of maximal
impulse was palpated in the anterior axillary line, 5th intercostal space.
Carotid upstrokes were brisk. Jugular venous pressure was approxi-
mately 8 cm of water. Peripheral pulses were full and intact bilaterally.
Abdominal examination revealed no organomegaly and no bruits were
heard. No evidence of peripheral edema, cyanosis, or clubbing was
found.
The patient's blood pressure initially was controlled with intravenous
nitroprusside. A gradual transition to oral therapy with hydralazine, 50
mg every 6 hours; furosemide, 20 mg twice daily; propranolol, 20 mg
every 6 hours; and alpha-methyldopa, 500mg every 6 hours, resulted in
a reduction in his blood pressure to 130/90 mm Hg. Prior to discharge
from the hospital, urine collection revealed the catecholamine excretion
to be within normal limits. A random plasma renin activity was 0.3 ngl
mllhr, and the plasma aldosterone concentration was 66 pg/mI. At
discharge the patient's BUN was 22 mg/dl. serum creatinine was 2.0
mg/dl, and sodium and potassium concentrations were normal. The
patient was returned to the care of his private physician.
One month following discharge, the patient's blood pressure was 174/
112 mm Hg. Hydralazine and alpha-methyldopa administration was
discontinued, propranolol was increased to 40 mg every 6 hours, and
minoxidil, 5 mg twice daily, was added to his drug regimen. His blood
pressure fell to 150/80 mm Hg, and he continued to do well without
evidence of congestive heart failure. One year following the initial
hospitalization, the patient developed musculoskeletal pain thought to
be secondary to degenerative joint disease. He was given indomethacin,
50mg orally three times daily, which relieved his pain. One month later,
follow-up examination disclosed a blood pressure of 210/140 mm Hg.
The minoxidil dose was raised progressively to 10 mg orally four times
daily, but the increase produced no significant effect. Alpha-methyldo-
pa, 500 mg twice daily, was restarted; it also was ineffective. The
patient's regimen eventually consisted of minoxidil, 10 mg three times
daily; alpha-methyldopa, 500 mg twice daily; furosemide, 40 mg twice
daily; captopril, 100 mg three times daily; and propranolol, 40 mg four
times daily. On this regimen, the blood pressure remained at 180/110
mm Hg, and the patient returned for further evaluation.
He was admitted to the MGH Clinical Research Center and was given
a 10 mEq sodium diet. Minoxidil, alpha-methyldopa, captopril. pro-
pranolol, and indomethacin were discontinued, but the patient contin-
ued to receive 40mg of furosemide daily. Urinary sodium excretion fell
to less than 10 mEq/day. The BUN and creatinine concentrations were
14 and 1.1 mg/dl, respectively; serum sodium concentration was 137
mEq/liter, and potassium concentration was 4.4 mEq/Iiter. Plasma renin
activity was 0.2 ng/ml/hr in the supine position and 1.1 ng/ml/hr after 3
hours in the upright position. The administration of 75 mg of captopril
orally lowered the blood pressure from 160/120mm Hg to 120/90mm Hg
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in the supine position, and from 170/125 to 100/65 in the upright position
(Fig. 1). The patient was discharged on a regimen of furosemide, 40 mg
twice daily, and captopril, 50 mg three times daily. His blood pressure
has remained approximately 130/75 mm Hg and he is asymptomatic.
Discussion
DR. RANDALL M. ZUSMAN (Director, Hypertension Division,
Cardiac Unit, Massachusetts General Hospital, and Assistant
Professor of Medicine, Harvard Medical School, Boston,
Mass.): The patient presented for discussion today provides an
opportunity for us to examine the therapeutic utility of inhibi-
tors of the renin-angiotensin cascade. I will focus on the
mechanism of action of the converting enzyme inhibitors and
will present evidence for a prostaglandin-dependent, non-renin-
mediated, antihypertensive effect of captopril, an orally active
converting enzyme inhibitor. Before discussing these issues,
however, I would like to review the present understanding of
the renin-angiotensin system.
Renin-angiotensin cascade
Angiotensin II stimulates vascular smooth muscle and causes
vasoconstriction. It also stimulates the adrenal gland and
causes increased aldosterone production and secondary sodium
retention. Because both vasoconstriction and sodium retention
increase blood pressure, considerable attention has been direct-
ed toward the development of a clinically useful inhibitor of the
renin-angiotensin cascade. As shown in Figure 2, three steps in
the generation of angiotensin II or its cellular action can be
attacked [1]. Renin, a proteolytic enzyme produced principally
by the juxtaglomerular apparatus, cleaves angiotensinogen, a
polypeptide synthesized by the liver, to produce angiotensin I,
which has no vasopressor activity. The angiotensin converting
enzyme, located principally within the pulmonary circulation
[21, then removes two amino acids from the angiotensin I
molecule and forms the octapeptide angiotensin 11; the latter
compound, through interaction with its receptor, constricts
smooth muscle and stimulates aldosterone biosynthesis. Inhibi-
tion of the renin-angiotensinogen reaction, blockade of the
angiotensin II receptor, or inhibition of converting enzyme
diminishes the physiologic effect of angiotensin II in vivo and
theoretically should decrease blood pressure in experimental
models of hypertension and in patients with renin-dependent
hypertension.
Renin antibodies. Renin has been purified from dog [3], hog
[4, 5], and human [6] kidney. Using purified renin as an antigen,
Haber and coworkers raised antibodies against the catalytic site
of the enzyme; these antibodies serve as a probe for the
investigation of the role of renin in normal cardiovascular
homeostasis and in experimental models of hypertension [7].
Dzau and colleagues demonstrated that such antibodies specifi-
cally prevent an increase in blood pressure in response to
injections of purified canine renin but do not prevent the
increase in blood pressure induced by angiotensin I or angioten-
sin II [8]. Similarly, these investigators showed that the injec-
tion of renin-specific antibody reduces the blood pressure in
sodium-depleted dogs, thus demonstrating that maintenance of
blood pressure in this pathophysiologic state is renin dependent
[7, 8]. Because the antibody is specific for renin, no significant
hemodynamic response to antibody injection occurs in animals
given a high-salt diet; under these conditions, the role of renin
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Fig. 1. Effect of capiopril on the blood pressure iviih subject in the
Supine position. The patient was receiving a diet containing 10 mEq
sodium and 100 mEq potassium per 24-hour period. Blood pressure in
the upright position fell from 170/125 mm Hg prior to captopril
administration to a nadir of 100/65 mm Hg.
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Fig. 2. The renin-angiorensin cascade and its inhibitors. (Adapted from
Ref. I.)
in maintaining blood pressure is minimal. The administration of
renin-specific antibody to dogs with acute renovascular hyper-
tension promptly eliminates renin from the peripheral circula-
tion and restores normal blood pressure. The redevelopment of
hypertension within 24 to 36 hours following antibody injection
coincides with the gradual metabolism of the renin-specific
antibody and the reappearance of renin activity in the peripher-
al circulation [7, 8]. Recently monoclonal, antihuman, renin-
specific antibodies have been isolated using cell fusion tech-
niques [9]. These antibodies do not bind non-renin proteolytic
enzymes and proteins, are species specific, and do not cross-
react with mouse, dog, bovine, or rat renin. Because they are
directed toward the catalytic site, these highly potent antibodies
are specific tools for physiologic studies in subhuman primates
and in humans. In much the same way that digitalis-specific
antibodies are used in the treatment of digitalis toxicity, renin-
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specific antibodies might become clinically valuable tools for
the treatment of accelerated or malignant hypertension in the
future [91.
Renin inhibitory peptides. Another method of inhibiting renin
activity is the use of a specific competitive inhibitor, based on
the structure of angiotensinogen. Since Skeggs and colleagues
reported that an octapeptide was the shortest peptide capable
both of serving as a substrate for renin and of functioning as a
competitive inhibitor of the renin-angiotensinogen reaction [10,
11], a number of analogues have been synthesized that exhibit
stronger inhibitory properties than those of this original octa-
peptide. Renin normally cleaves a leucine-leucine bond in
angiotensinogen. Burton and coworkers reported that the sub-
stitution of phenylalanine for these leucine residues yielded a
molecule that served as a poor substrate for renin's proteolytic
activity, and which prevented its reaction with angiotensinogen
by competitive inhibition. The addition of a proline residue at
the amino terminus and a lysine residue at the carboxy terminus
of this molecule produced a peptide with inhibitory properties
in vivo [121.
Is this renin inhibitory peptide effective in experimental
models of hypertension? Its intravenous injection caused a
reduction in blood pressure in sodium-depleted M. fasicularis
monkeys that was not observed following injection of the
peptide into normotensive, sodium-replete animals [12]. Be-
cause peptide infusion blocked the pressor response to purified
human renin but not to angiotensin I or angiotensin II in these
animals, the investigators concluded that this renin inhibitory
peptide had no effect on the converting enzyme, but that its
hemodynamic response was specific for inhibition of the renin-
angiotensinogen reaction. In a separate study, administration of
this renin inhibitory peptide in a monkey model of acute
renovascular hypertension promptly lowered blood pressure,
presumably because of inhibition of the renin-angiotensinogen
reaction [131.
Clinical investigation of the renin inhibitory peptide extended
these experimental findings. When we administered the peptide
to sodium-depleted humans, we observed a more complex
hemodynamic response [14]. While the subjects were in the
supine position, intravenous administration at rates up to 1 mgI
kglmin reduced blood pressure only moderately. When these
individuals stood up, blood pressure fell to zero (Fig. 3). In
addition, in contrast to the tachycardia that usually accompa-
flies vasodilation in sodium-depleted subjects, the nadir of the
blood pressure response frequently occurred in association with
a marked sinus bradycardia. These findings suggest activation
of the parasympathetic nervous system by the renin inhibitory
peptide.
In a preliminary study, we determined the effect on blood
pressure of giving the renin inhibitory peptide to one subject
after administration of a high-salt diet (200 mEq/day). Because
plasma renin activity is known to be suppressed under these
conditions, we anticipated a minimal hypotensive response to
inhibition of the renin-angiotensin cascade. Strikingly, the
subject's blood pressure fell markedly in both supine and
upright positions, and the decrease again was associated with
bradycardia (Fig. 4). In the supine position, blood pressure fell
from 118/68 to 66/0 mm Hg; in the upright position, blood
pressure decreased from 105/80 mm Hg to an undetectable
value. During renin inhibitory peptide infusion, the plasma
renin activity of this one subject increased. This finding sug-
gests that effective blockade of the generation of angiotensin II
occurred with release of the negative feedback pathways that
normally suppress renin release. In contrast to the fall in plasma
aldosterone concentration that frequently accompanies the inhi-
bition of the renin-angiotensin system with other substances,
however, plasma aldosterone concentration increased during
renin inhibitory peptide infusion.
These data suggest that, although designed as a specific
inhibitor of the renin-angiotensinogen reaction, the renin inhibi-
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Fig. 3. Effect on blood pressure of infusion of
a renin inhibitory peptide into normal
volunteers on a JO mEq sodiuml24 hr diet in
the supine (A) and upright (B) positions.
(Reproduced from Ref. 14.)
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tory peptide has multiple mechanisms of action. In addition to
inhibiting peripheral renin activity, the peptide might inhibit
renin within the blood vessel wall, brain, or other sites. If so, a
previously unrecognized role for these tissue renins in the
regulation of cardiovascular homeostasis will be unmasked.
The peptide might produce parasympathetic stimulation that
results in sinus bradycardia, venous dilation, and a fall in
cardiac output. Alternately, it might interact with another
system and release vasodilating substances. Finally, the peptide
might activate cardiac reflexes such as the Bezold-Jarisch
reflex, which results in peripheral vasodilation, bradycardia,
and hypotension.
Other investigators also have explored the hemodynamic
effects of renin-specific inhibitors. Szelke and coworkers syn-
thesized a renin-specific inhibitor that reduces blood pressure in
sodium-depleted conscious dogs [15]. In vitro, this substance
inhibits the proteolytic activity of human, canine, and rat renin,
but its effect on blood pressure homeostasis in human subjects
has not been tested. Similarly, Boger and colleagues have
developed a highly potent renin inhibitor through substitution of
a statine (a chemical amino acid analogue) residue in the
angiotensinogen peptide sequence [161. Administration of this
material to sodium-depleted dogs also decreased blood pressure
and, like the administration of the previously described renin
inhibitory peptide to normal volunteers [14], reduced heart rate
instead of producing tachycardia [17]. These studies lend cre-
dence to the suggestion that although renin inhibitory peptides
were synthesized as specific inhibitors of the renin-angiotensin-
ogen reaction, they might have multiple mechanisms of action,
either dependent or independent of the renin-angiotensin
cascade.
Angiotensin II receptor antagonists
A similar multiplicity of activity characterizes the action of
angiotensin analogues, competitive antagonists of the angioten-
sin II receptor. The substitution of sarcosine and alanine for the
naturally occurring amino acids at positions one and eight in the
angiotensin II molecule yields the highly competitive receptor
antagonist, saralasin [18]. Administration of this peptide to
experimental animals with acute renovascular hypertension and
to patients with high-renin hypertension significantly reduces
blood pressure. In low-renin states, however, saralasin pos-
sesses angiotensin II agonistic activity and increases blood
pressure [19]. The clinical utility of this compound thus is
limited to the identification of renin-dependent states, and even
here its lack of specificity has prevented its widespread adop-
tion as a diagnostic tool.
Converting enzyme inhibition
The importance of the angiotensin converting enzyme was
first recognized by Skeggs and colleagues, who found that the
product of the reaction of crudely purified porcine renin with
equine angiotensinogen was a mixture of two peptide hormones
[20]. Subsequent study revealed that production of the second
hormone, later shown to be angiotensin II, was due to contami-
nation of the angiotensinogen substrate by an enzyme that
released a dipeptide from the carboxy terminus of angiotensin I
[21, 22]. Both angiotensins had vasopressor properties follow-
ing intravenous infusion. But Helmer, using a superfusion assay
system measuring rabbit aortic strip contraction, later identified
angiotensin II as the biologically active moiety [22]. The
vasopressor response to angiotensin I infusion therefore was
attributable to its conversion to angiotensin II. Ng and Vane
demonstrated that angiotensin I was converted to angiotensin II
during passage through the pulmonary circulation [23, 241.
Their work suggested that a pulmonary enzyme in intimate
contact with the blood as it passed through the pulmonary
circulation accounted for the rapid metabolism of the precursor
peptide to angiotensin II. Subsequent studies have demonstrat-
ed that the converting enzyme is a component of the vascular
endothelium of many tissues and that its localization on the
luminal surface of the plasma membrane is ideally suited for its
function [21. Because of the parallelism of proteolytic deactiva-
tion and activation of bradykinin and angiotensin I, respective-
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ly, during transit through the pulmonary circulation, it was
suggested that the same protein, the angiotensin converting
enzyme, might be responsible for the catalysis of both reactions
[25]. In 1968 Bakhte reported that bradykinin potentiating
factor, a mixture of polypeptides isolated from venom of the
snake Bothrops jararaca, inhibited the conversion of angioten-
sin Ito angiotensin II by canine pulmonary tissue [26]. Ferreira
previously had demonstrated that this peptide mixture potenti-
ated the action of bradykinin on smooth muscle by inhibiting
kininase activity and kinin degradation [27]. After purifying
individual peptides from the snake venom, Ferreira and col-
leagues confirmed that the substances could inhibit both angio-
tensin converting activity and bradykininase activity of a pul-
monary homogenate [28, 29].
The first angiotensin converting enzyme inhibitor studied in
humans was a synthetic nonapeptide then known as SQ20881
and later named teprotide. Teprotide blocked the vasopressor
response to intravenous infusions of angiotensin I, and effec-
tively reduced blood pressure in patients with elevated plasma
renin activity [30]. Because of teprotide's short duration of
action and its limitation to parenteral administration, however,
its clinical utility is limited.
Studies with synthetic substrates and inhibitors of angioten-
sin converting enzyme led to the conclusion that the angiotensin
converting enzyme was a carboxypeptidase similar to pancreat-
ic carboxypeptidase A [31]. Additional studies revealed that the
angiotensin converting enzyme is a zinc-containing metallopro-
tein, also similar to carboxypeptidase A [32]. It therefore was
assumed that the site and mechanism of action of the angioten-
sin converting enzyme would be similar to those of the pancre-
atic enzyme [33]. In 1973 Byers and Wolfenden reported that d-
2-benzylsuccinic acid was a potent competitive inhibitor of
carboxypeptidase A. This competitive activity was thought to
be secondary to the simultaneous and stereospecific interaction
of the inhibitor with three substrate binding sites at the active
site of the carboxypeptidase enzyme [34]. Reasoning that
similar stereospecificity might characterize the active site of
angiotensin converting enzyme, Cushman and colleagues un-
dertook a sequential analysis of compounds that might serve as
orally active converting enzyme inhibitors. These investigators
demonstrated that an analogue of proline, D-3-mercapto-2-
methyl-propanoyl-l-proline, was a highly specific inhibitor of
the converting enzyme in vitro [35]. The alpha-methyl group
and the carboxyl groups of proline later were shown to interact
with hydrophobic sites of the angiotensin converting enzyme.
The mercapto substitution on the beta carbon resulted in
specific interaction with the zinc atom, which is a crucial
portion of the catalytic site of the enzyme, and accounts for the
marked inhibitory properties of the molecule [36]. This new
proline analogue, originally known as SQ14225 and later named
captopril, was found to be a potent competitive inhibitor of
converting enzyme activity.
Based on the foregoing discussion of the synthesis of the
converting enzyme inhibitor captopril and the properties of the
converting enzyme as both the activator of angiotensin II and
the deactivator of bradykinin, it was assumed that the response
of animals and humans to captopril could be explained by
changes in the levels of angiotensin II and bradykinin. Howev-
er, this assumption cannot explain many of the responses to
captopril in normal and hypertensive animals and humans. In
AngiotensinI converting
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Fig. 5. Theoretical mechanism of action of captopril. Inhibition of the
angiotensin converting enzyme (kininase II) was theorized to result in a
fall in plasma angiotensin II and aldosterone concentration and a rise in
plasma bradykinin concentration. (Reproduced from Ref. 37.)
renin-independent models of hypertension, the efficacy of cap-
topril can only be explained by a non-renin—mediated antihyper-
tensive activity. It is my view that the non-renin—mediated
activity of captopril is accounted for by captopril's stimulation
of arachidonic acid release and a consequent increase in synthe-
sis of vasodilatory prostaglandins. The following discussion
outlines the evidence that captopril has antihypertensive prop-
erties that are not mediated by renin and that prostaglandins
account for those properties.
The theoretical mechanism of action of a converting enzyme
inhibitor is represented in Figure 5 [37]. Inhibition of the
converting enzyme by captopril decreases generation of angio-
tensin II from angiotensin I. The decrease in angiotensin II
diminishes vasoconstrictor activity and decreases adrenal
aldosterone biosynthesis. The consequent decrease in vasocon-
strictor activity (and in theory, a sodium diuresis) thus lowers
blood pressure. Because angiotensin II participates in a nega-
tive-feedback loop that inhibits renin release by the juxtaglo-
merular apparatus, the fall in angiotensin II concentration
produces a reflex increase in renin activity and an increased
concentration of angiotensin I. Because of the inhibition of the
converting enzyme, however, this increase in angiotensin I
concentration cannot elevate plasma angiotensin H concentra-
tion. In addition, because the converting enzyme is responsible
for the destruction of bradykinin, the accumulation of increased
concentrations of the vasodilator bradykinin reduces peripheral
vascular resistance and lowers systemic blood pressure. Many
clinical and laboratory studies have confirmed that the adminis-
tration of teprotide or captopril significantly decreases plasma
angiotensin II concentration, plasma aldosterone concentra-
tion, and blood pressure. Systemic vascular resistance falls and
cardiac output is maintained or increased, consistent with a
reduction in the vasoconstrictor effects of angiotensin II [38].
The acute response to converting enzyme inhibition appears to
correlate closely with the pretreatment plasma renin activity,
and the response thus is consistent with the theoretical mecha-
nism of action of these compounds that I have outlined [39].
Captopril's effect on the kinin system. Although theoretically
expected to increase plasma kinin levels, converting enzyme
inhibition could not be consistently proved to alter circulating
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kinin concentration. Occasional studies have reported an eleva-
tion in plasma kinin concentration [40—45], but most investiga-
tors have failed to demonstrate any significant increase [46—56].
Kinins are local mediators rather than circulating substances,
and many enzymes other than the angiotensin converting
enzyme can inactivate them through kininase activity. There-
fore, a failure to demonstrate an increase in circulating kinin
concentration is not totally unexpected. Carretaro and col-
leagues examined the role of kinins in the acute and chronic
hypotensive effect of converting enzyme inhibitors, using spe-
cific antikinin antibodies that block the depressor effect of
exogenously administered bradykinin. Because the administra-
tion of antikinin antibodies had no effect on the hypotensive
response to captopril in sodium-depleted rats, the authors
concluded that the antihypertensive activity of captopril in this
model could be attributed solely to its inhibition of the renin-
angiotensin cascade. Administration of the antikinin antibodies
in the spontaneously hypertensive rat or in 2-kidney, 1-clip
hypertensive rats significantly attenuated the decrease in blood
pressure following captopril administration, however [57]. Al-
though a consistent change in plasma kinin levels has not been
found, the possibility that tissue kinins accessible to the anti-
kinin antibodies played a role in the antihypertensive activity of
captopril cannot be excluded by such studies.
Non-renin—mediazed hypotensive effect of converting enzyme
inhibition. In addition to the possible role of kinins in the
antihypertensive activity of captopril, additional evidence for a
non-renin—mediated antihypertensive activity of captopril was
obtained in studies involving experimental animals and normo-
tensive and antihypertensive humans. Marks and coworkers
reported that captopril decreased blood pressure by 15% in
normal rats. Following nephrectomy, the blood pressure of the
animals fell by 30%; however, the administration of captopril
produced a further 10% drop in blood pressure despite the
absence of renin in the peripheral circulation. In animals with
early Goldblatt 2-kidney, 1-clip hypertension (a model known to
be renin dependent), captopril produced a 50% decrease in
blood pressure that was associated with marked elevations in
plasma renin activity. On the other hand, in rats with late 2-
kidney, I-clip hypertension (a model of hypertension thought
not to depend on the renin-angiotensin system), captopril also
produced a substantial drop in blood pressure. In addition, in
animals made hypertensive by the chronic administration of
deoxycorticosterone and a high-salt diet, captopril reduced
blood pressure by 20 mm Hg. These rats have markedly
suppressed plasma renin activity and represent an experimental
model of volume-expansion, low-renin hypertension [58].
Moreover, in salt-depleted rats in which the endogenous renin-
angiotensin system has been blocked by infusion of the compet-
itive angiotensin II antagonist saralasin, captopril further re-
duces blood pressure [59].
Muirhead and colleagues reported that the administration of
captopril to rats receiving exogenous angiotensin Ii and high-
salt diets significantly decreased blood pressure [60]. The
reduction of blood pressure in this experimental model could
not be explained on the basis of a reduction in plasma angioten-
sin II concentration, as the exogenous administration of angio-
tensin II maintained a high level of this vasoconstrictor poly-
peptide in the peripheral circulation, raised the blood pressure
to hypertensive levels, and suppressed endogenous renin re-
lease. In contrast, Textor and coworkers reported that chronic
angiotensin II infusion in conscious rats prevented any hemody-
namic response to converting enzyme inhibition. These investi-
gators concluded that neither bradykinin nor vasodilator hor-
mones contributed to the long-term antihypertensive activity of
captopril [61].
Additional studies by Muirhead and associates revealed that
administration of captopril significantly decreases blood pres-
sure in spontaneously hypertensive rats, an experimental model
in which the hypertension is thought to be independent of the
renin-angiotensin system [62]. The decrease in peripheral vas-
cular resistance in these studies also suggests a non-renin—
mediated antihypertensive activity of captopril.
If captopril's antihypertensive activity were solely due to the
antagonism of the generation of angiotensin II by renin in the
peripheral circulation, bilateral nephrectomy would be expect-
ed to totally eliminate any hemodynamic response to the
administration of this converting enzyme inhibitor. Leslie and
coworkers reported that captopril failed to reduce the blood
pressure of 5 anephric patients. These authors concluded that if
captopril had an angiotensin-independent antihypertensive ac-
tivity, this action would depend on the presence of functional
renal tissue [63]. Man ln't Veld, however, reported that the
volume status of anephric patients dramatically affected the
hemodynamic response to captopril. Salt- and water-repleted
patients showed no response to captopril prior to hemodialysis.
Following hemodialysis and relative salt and water depletion,
however, captopril significantly reduced blood pressure 164,
65].
The relative activities of saralasin and captopril in early and
late Goldblatt 2-kidney, 1-clip hypertension were studied by
Thurston and colleagues, They found that in the early phase of
hypertension, both saralasin and captopril reduced blood pres-
sure significantly. In the chronic phase of hypertension, howev-
er, only captopril evoked a statistically significant decrease in
blood pressure, again suggesting that captopril has an antihy-
pertensive effect independent of the renin-angiotensin system.
They further found that in salt-loaded or salt-restricted animals,
or those with chronic 2-kidney Goldblatt hypertension, tepro-
tide produced a reduction in blood pressure beyond that ob-
served following angiotensin receptor blockade with saralasin
[66].
An additional approach to the study of a possible non-renin—
mediated antihypertensive activity of captopril was reported by
Tree and Morton. Investigating the blood pressure of sodium-
loaded dogs as a function of the plasma angiotensin II concen-
tration before and after captopril administration, they found
that a higher concentration of angiotensin II was required to
produce the same blood pressure in dogs that had received
captopril than in those animals that had not [67]. In a similar
study, Swartz and coworkers found that following infusion of
teprotide, the plasma angiotensin II level had to be raised by a
mean value of 45 pg/mI above the control plasma angiotensin II
concentration to maintain the same blood pressure. Because an
increase in plasma bradykinin levels following converting en-
zyme inhibition was found in this study, the authors suggested
that one or more other factors, perhaps bradykinin, was respon-
sible for the greater-than-expected hypotensive response to
converting enzyme inhibition based on the fall in angiotensin II
concentration [45]. Crantz and colleagues reported that capto-
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pril elicited a greater drop in blood pressure in a group of
patients with normal renin, essential hypertension than did
teprotide. Unlike the response to teprotide, captopril adminis-
tration was not associated with an increase in plasma kinin
concentration [46]. Finally, in a study of 26 hypertensive
patients, Fagard and coworkers reported that captopril had a
greater antihypertensive effect than did saralasin [68]. Their
findings again suggested a non-renin—mediated antihypertensive
activity for this orally active converting enzyme inhibitor.
Prostaglandin synthesis and the non-renin—mediated antihy-
pertensive effect of converting enzyme inhibitors. Vinci and
coworkers published the first study suggesting that the non-
renin—mediated antihypertensive activity of converting enzyme
inhibitors was due to prostaglandin release. They infused
teprotide at a rate sufficient to lower blood pressure by 10 mm
Hg in subjects with mild essential hypertension. The concentra-
tion of prostaglandin E in arterial blood, as measured by
radioimmunoassay, increased threefold during teprotide infu-
sion [69]. The authors also observed the anticipated rise in
plasma renin activity and angiotensin I concentration as well as
a fall in plasma angiotensin II and aldosterone concentrations.
Plasma arterial bradykinin concentration remained unchanged
during teprotide infusion. Swartz and coworkers subsequently
reported the effect of captopril on the prostaglandin system in
normal subjects on both high- and low-sodium diets. Captopril
induced a significant increase in the excretion of the 13,14-
dihydro-15-keto metabolite of prostaglandin E2. No changes in
plasma levels of 6-keto prostaglandin F2a, the major metabolite
of prostacyclin, or thromboxane B2, the major metabolite of
thromboxane A2, were observed. The depressor response to
captopril correlated closely with the change in urinary prosta-
glandin E2 metabolite excretion, but did not correlate with
changes in plasma angiotensin II and kinin levels [70].
Abe and coworkers reported an increase in urinary prosta-
glandin E excretion following captopril administration in pa-
tients with essential hypertension. Administration of a prosta-
glandin synthesis inhibitor to these same patients abolished the
antihypertensive activity of captopril [71]. Moore and col-
leagues reported an increase in the urinary excretion of the
prostaglandin E2 metabolite following captopril administration
in 31 sodium-restricted patients with essential hypertension. In
18 of these patients, the administration of indomethacin or
aspirin was associated with decreased prostaglandin E2 excre-
tion and a significant blunting of the depressor response to
captopril [72]. Similarly, Silberbauer et al [73], Ogihara et al
[74], Witzgall et al [75], and Goldstone et al [76] have demon-
strated that the administration of a prostaglandin synthesis
inhibitor blunts the hemodynamic response to captopril in
hypertensive and normal subjects. Finally, Provoost reported
that aspirin and indomethacin diminished the hemodynamic
response to captopril administration in rats [77].
This series of studies led to the conclusion that the antihyper-
tensive activity of captopril is not solely related to its inhibition
of the renin-angiotensin cascade. Nor is there consistent evi-
dence to suggest that an increase in plasma kinin concentration
plays an important role in the reduction in blood pressure
following captopril administration. The accumulated studies of
captopril's effect in models of low-renin hypertension, as well
as the evidence for an increase in plasma and urinary prosta-
glandins, and the inhibitory effect of prostaglandin synthesis
inhibitors on captopril's hemodynamic response, suggest that
captopril has major prostaglandin-mediated antihypertensive
activity.
In-vivo studies have shown that captopril-stimulated prosta-
glandin biosynthesis and release play an important role in the
hypotensive response to this compound. The prostaglandin-
mediated vasodilation is particularly important in the hypoten-
sive response to captopril in experimental animals or in humans
with a low plasma renin activity. But what is the cellular
mechanism by which captopril stimulates prostaglandin biosyn-
thesis? I will now review the cellular regulation of arachidonic
acid release and prostaglandin biosynthesis, and describe our
studies on the effect of captopril on prostaglandin biosynthesis.
The chemical pathways leading to prostaglandin biosynthesis
have been exquisitely elucidated in numerous laboratories [78].
Prostaglandins are derived from arachidonic acid, a polyunsatu-
rated fatty acid stored within the phospholipid storage pool of
every cell in the body. Activation of a phospholipase—predomi-
nantly phospholipase A2, but phospholipase C in some tis-
sues—results in the release of arachidonic acid, which subse-
quently is converted to the precursor prostaglandin G2 by the
cyclooxygenase enzyme. The cyclooxygenase enzyme, sensi-
tive to the inhibitory effects of nonsteroidal antiinflammatory
drugs, is specifically acetylated by aspirin, thus rendering the
enzyme permanently incapable of catalyzing arachidonic acid
metabolism. Prostaglandin G2 is converted to prostaglandin E2
or prostaglandin F2a by peroxidation and isomerization, to
thromboxane A2 by thromboxane synthetase, or to prostacyclin
by prostacyclin synthetase. Prostaglandin E2 is a potent vasodi-
lator, but because it is rapidly metabolized in a single passage
through the pulmonary vasculature, it probably does not play a
significant role as a vasodilating hormone [79]. However, it has
significant effects on adenylcyclase and cyclic AMP metabo-
lism, and it probably is important in the regulation of local
hormonal action [37]. Prostaglandin F2a, in contrast to prosta-
glandin E2, is a potent vasoconstrictor. Like PGE2, however, it
is rapidly metabolized by the pulmonary circulation, and it
probably does not function as a circulating vasoconstricting
hormone. The production of prostaglandin E2 and prostaglandin
F2 locally might have a significant effect on individual vascular
beds. Thromboxane A,, a strikingly potent vasoconstrictor [80]
predominantly synthesized in the platelet, is a potent stimulant
of platelet aggregation [81]. Although thromboxane A2 can be
synthesized by other tissues, it probably is not a vasoconstrict-
ing hormone. Prostacyclin, a potent vasodilating substance
produced predominantly by the vascular endothelium [82],
causes vasodilation and inhibition of platelet aggregation. Be-
cause prostacyclin is stable in aqueous solution and has a half-
life in biologic systems of up to 5 minutes, it might be an
important circulating vasodilator or antiaggregating substance
[83].
Although the biochemistry of prostaglandin biosynthesis has
been well elucidated, the study of the regulation of cellular
prostaglandin biosynthesis has been limited by the lack of a
model system in which the controlling factors affecting prosta-
glandin production could be identified. Neither whole-organ
perfusion nor tissue slices provide sufficient control for such
experimental studies, especially when an individual organ can
have multiple prostaglandin biosynthetic sites, and the function
of one cellular system might affect prostaglandin biosynthesis
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by a second cell type within that same organ. In no tissue is this
more apparent than in the kidney, where a minimum of 5 cell
types—the vascular endothelium, the mesangial cells of the
glomerulus, the epithelial cells of Bowman's capsule, the reno-
medullary interstitial cells, and the epithelial cells of the collect-
ing tubule—can produce prostaglandins [37].
The development of a technique for the isolation of reno-
medullary interstitial cells in tissue culture provided an oppor-
tunity for the study of the regulation of cellular prostaglandin
biosynthesis [841. Previous studies in our laboratory have
shown that this cell line makes significant quantities of prosta-
glandins E2 and in tissue culture. The addition of vasoac-
tive peptides such as angiotensin II, vasopressin, and impor-
tantly, bradykinin, causes an increase in prostaglandin synthe-
sis [85]. Incubation of these cells with radioactively labeled
arachidonic acid allows for identification of the endogenous
arachidonic acid storage pool. Subsequent stimulation by vaso-
active peptides activates the phospholipase and releases arachi-
donic acid from the phospholipid fraction; the arachidonic acid
subsequently is converted to prostaglandins [68]. This prosta-
glandin synthetic response to angiotensin II stimulation has
been studied in detail, and the interaction of angiotensin II with
its receptor, the binding characteristics of this receptor, the
stimulation of phospholipase activity, and the release of arachi-
donic acid and subsequent conversion to prostaglandin E2
demonstrate parallel dose-response curves and receptor binding
kinetics [871.
Using renomedullary interstitial cell tissue culture, we found
that captopril produced up to a 30-fold stimulation of prosta-
glandin biosynthesis (Fig. 6). Half-maximal stimulation of pros-
taglandin biosynthesis occurred at a captopril concentration of
approximately 8 M. This concentration is similar to the plasma
level of drug achieved following administration of captopril to
normotensive or hypertensive subjects. When we investigated
the effect of captopril on the release of radiolabeled arachidonic
acid, we found that captopril significantly increased arachidonic
acid release (Table 1). Thus, like the vasoactive peptides,
Arachidonic
PGE2 synthesis
ng/rig of
protein per hour
acid release
fmoleIg of
protein per hour
Control 0.3 0.1 42 4
Captopril (7.5 M) 2.4 0.4 3425 269b
Bradykinin (20 nM) 3.0 0.6b 3428 427'
Captopril + bradykinin 8.1 0.8c 21629 668c
captopril stimulates prostaglandin biosynthesis through activa-
tion of the phospholipase and through an increase in the rate of
release of the precursor fatty acid leading to prostaglandin E2
biosynthesis. In similar studies, captopril increased prostacy-
din biosynthesis from aortic vascular endothelium (LEVINE L,
personal communication) and increased prostacyclin and pros-
taglandin E2 biosynthesis by isolated renal glomeruli [88].
Using the in-vitro renomedullary interstitial cell system, it
has been possible to elucidate the mechanism by which convert-
ing enzyme inhibition, prostaglandins, and bradykinin interact
in a way that might explain the captopril-related antihyperten-
sive response. Previous studies have demonstrated that potenti-
ation of bradykinin following captopril administration was
secondary to the stimulation of prostaglandin biosynthesis,
particularly in the kidney [89]. Mullane and Moncada reported
increased prostacyclin release following bradykinin administra-
tion in beagles [90]. The administration of a prostaglandin
synthesis inhibitor markedly attenuated the potentiation of
bradykinin following captopril administration. Both captopril
and bradykinin independently stimulated arachidonic acid re-
lease and prostaglandin biosynthesis by renomedutlary intersti-
tial cells in tissue culture [37]. However, incubation of cells in
the simultaneous presence of captopril and bradykinin in-
creased prostaglandin biosynthesis and arachidonic acid re-
lease; these alterations exceeded the additive effects of the two
agents' independent effects (Table 1).
The augmented prostaglandin synthesis in response to capto-
pril and bradykinin is particularly noteworthy in view of the
data of Vinci et al [69]. In addition to the increase in prostaglan-
din biosynthesis observed following converting enzyme inhibi-
tion with teprotide, Vinci and coworkers found that the reduc-
tion in blood pressure correlated with the increase in arterial
blood prostaglandin concentration of their patients; these same
patients were found to have significantly increased urinary
kinin excretion. A small number of hemodynamic nonre-
sponders failed to demonstrate the increase in prostaglandins
and urinary kinin. An increase in urinary kinin excretion was
observed by Olsen and Arrigoni-Martelli following captopril
administration and blood pressure reduction in normal con-
scious dogs [91].
Mechanism of action of captopril: Summary
A summary of the proposed mechanism of action of captopnl
is shown in Figure 7. Inhibition of the angiotensin converting
Table 1. Effect of captopril on basal and hormone-stimulated PGE2
synthesis and arachidonic acid release by renomedullary interstitial
cells in tissue cultures5
'A0 4
A)
'q)
2
'A0
0 0 20 50 100
Captopril, pm
Fig. 6. Effect of captopril on prostaglandin E2 biosynthesis by rabbit
renomedullary interstitial cells in tissue culture. (Reproduced from Ref.
37.)
2 5 10
Mean SEM,
N=6
Each value represents the mean SEM, N = 8. (Reproduced from
Ref. 37).
b p < 0.01 versus control.
P < 0.01 versus control, captopril, or bradykinin.
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Angiotensinogen
Renin
Inactive peptides , Angiotensin I
Arachidonic acid- CAPTOPRIL- - Angiotensin CAPTOPRIL
converting
enzymestorage pool
Kinins / \Angiotensin II
1Phospholipase
(Tissue vs. plasma)
Arachidonic acid Blood pressure
Cyclooxygenase
PGE2 — Sodium retention
PG Endoperoxides
y, lung) /
PGl
(Lung, blood vessel
endothelium)
enzyme in the pulmonary circulation reduces the rate of conver-
sion of angiotensin Ito angiotensin H. The fall in angiotensin II
concentration and the concomitant decrease in plasma aldoster-
one concentration cause decreased vasoconstriction and a loss
of sodium that lead to a drop in blood pressure. This effect is
predominant in the sodium-depleted state and in models of high-
renin hypertension. Although the angiotensin converting en-
zyme is also responsible for destruction of bradykinin, no
consistent and significant change in plasma bradykinin concen-
trations can be documented, probably because of the multiple
other enzymes with kininase activity that are not affected by
captopril. Nonetheless, under certain circumstances the admin-
istration of an antikinin antibody attenuates the antihyperten-
sive response following captopril administration. The lack of a
significant increase in plasma kinin concentrations, yet the
sensitivity under certain conditions to the effects of antikinin
antibodies, might point to the importance of tissue rather than
plasma kinins in this antihypertensive mechanism. In particu-
lar, augmented kinin formation by the kidney, as reflected by
the increase in urinary kinin excretion following converting
enzyme inhibition in humans and experimental animals, might
reflect the inhibition of kinin destruction in tissue systems as
opposed to in the plasma. Finally, captopril directly stimulates
prostaglandin biosynthesis by renal and vascular endothelium
and raises the arterial concentration of vasodilating prostaglan-
dins. This increase in prostaglandin biosynthesis might accrue
from the direct effects of captopril or from the accentuation of
the stimulation of prostaglandin biosynthesis by bradykinin.
The vasodilation due to increased arterial prostaglandin con-
centrations is the major reason for the antihypertensive activity
of captopril in the sodium-replete state and in models of low-
renin hypertension.
The mechanism of the synergistic effect of captopril and
bradykinin on cellular prostaglandin biosynthesis remains un-
known. Although peptide hormone-stimulated prostaglandin
biosynthesis depends on increased calcium influx following
receptor activation [92], captopril-stimulated prostaglandin bio-
synthesis does not appear to be a calcium-dependent process
(ZUSMAN R, unpublished observations). It is possible, howev-
er, that captopril and bradykinin interact so as to result in a
greater-than-additive increase in prostaglandin biosynthesis.
The interaction of the converting enzyme inhibitors and
prostaglandin biosynthesis might account in part for the revers-
ible renal failure in patients with bilateral renal artery stenosis
and in patients with renal artery stenosis in a solitary kidney
[94—97]. With normal renal vasculature, administration of a
converting enzyme inhibitor augments renal blood flow because
of decreased vascular resistance of the preglomerular renal
arteriole [98, 99]; the decrease in preglomerular renal arteriolar
resistance may be the result of an increase in the concentration
of vasodilator prostaglandins in the arterial blood. The postglo-
merular efferent arterial vasculature simultaneously dilates be-
cause of diminished angiotensin Il-mediated vasoconstriction
[100, 1011. Under normal conditions, the net effect of the fall in
afferent as well as efferent arteriolar resistance is an increase in
glomerular filtration rate. With significant renal artery stenosis,
however, maximal poststenotic renal afferent arteriole vasodila-
tion is present prior to captopril administration. Because the
stenosis is a fixed and structural obstruction to renal blood
flow, and because of maximal afferent arteriolar dilation due to
the decreased renal perfusion pressure, angiotensin converting
enzyme inhibition decreases intrarenal angiotensin II concen-
tration and markedly dilates the efferent arteriole. In patients
with bilateral renal artery stenosis or renal artery stenosis in a
solitary kidney, the reduction of efferent arteriolar resistance
reduces glomerular filtration pressure, filtration fraction, and
glomerular filtration rate, and induces a deterioration of renal
function.
Finally, the patient presented today demonstrates the clinical
significance of the interaction of captopril, the bradykinin
system, and prostaglandins. This patient had low-renin, essen-
tial hypertension. His low plasma renin activity would have
suggested that his clinical response to converting enzyme
inhibition would be minimal. Nonetheless, following sodium
restriction, captopril strikingly reduced his blood pressure in
both the supine and upright positions. A significant component
of the reduction of blood pressure in patients such as the one
presented today no doubt results from the stimulation of
Fig. 7. Biochemical effects of angiotensin con-
verting enzyme inhibition following captopril
administration.
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prostaglandin biosynthesis by this unique compound. The dete-
rioration of blood pressure control in this patient following
therapy with indomethacin for musculoskeletal pain reflects the
potential clinical significance of the relationship between con-
verting enzyme inhibitors and nonsteroidal antiinflammatory
drugs as well as the possibility of an adverse clinical response in
patients simultaneously treated with these substances.
Questions and answers
DR. JOHN T. HARRINGTON: Does captopril have a residual
antihypertensive effect that is not explained on the basis of
interference with an effect on angiotensin II, bradykinin, or
prostaglandins?
DR. ZUSMAN: Demonstrating such a residual effect would
require a relatively complex experiment that could make use of
currently available techniques. The first step would be elimina-
tion of the effects of the renin system by administering the
renin-specific antibody, then eliminating the prostaglandin sys-
tem by administering a large dose of nonsteroidal antiinflamma-
tory drug, and finally administering a maximal dose of a
converting enzyme inhibitor. It would be of particular interest
to compare the effects of captopril and a non-sulthydryl—
containing converting enzyme inhibitor such as MK-421 to
assess the relative potency of those two agents under these
conditions. That study has not been done, but it is something
we are contemplating as we attempt to evaluate the antihyper-
tensive effect of the renin inhibitory peptide currently under
investigation in my laboratory. We will try to dissect the renin-
and non-renin—mediated effects of our peptide using the antire-
nm antibody, and hopefully we will have some information
along those lines in the future.
DR. NIc0LA0s E. MADIAS: As you know, vasopressin has
been implicated in the pathogenesis of several models of
hypertension. Moreover, angiotensin II stimulates vasopressin
secretion. Are there any data regarding changes in vasopressin
levels following administration of captopril?
DR. ZUSMAN: Captopril decreased urinary vasopressin excre-
tion in spontaneously hypertensive rats [102], and in patients
with essential [103, 104] and renovascular hypertension [104].
However, in Brattleboro strain vasopressin-deficient rats cap-
topril reduced blood pressure [105]. Thus the antihypertensive
activity of captopril does not appear to depend on the reduction
of antidiuretic hormone concentration.
DR. JORDAN J. COHEN: You indicated that angiotensin II as
well as captopril stimulate prostaglandin activity. This raises
the possibility that increased angiotensin I levels might be
responsible for the effect of captopril on this system. Does
angiotensin I have any effect on prostaglandins?
DR. ZUSMAN: The increase in angiotensin I concentration
following captopril administration is probably three- or four-
fold. But the concentration of angiotensin I required to produce
equivalent stimulation of prostaglandin biosynthesis is approxi-
mately 100 to 1000 times higher than the concentration of
angiotensin H having an equivalent effect. The increase in
prostaglandin biosynthesis therefore cannot be explained on the
basis of a small increase in angiotensin I concentration.
DR. COHEN: Are the doses of captopril currently used the
minimum doses for effective inhibition of angiotensin II
production?
DR. ZUSMAN: Doses as low as 25 or 50 mg inhibit the
converting enzyme, reduce angiotensin II concentration, and
reduce blood pressure [106].
DR. COHEN: Are those doses also effective in increasing
prostaglandins?
DR. ZUSMAN: Yes, Swartz and coworkers used a single dose
of captopril in their study and demonstrated an increase in
prostaglandin synthesis [70].
DR. RICHARD KOPELMAN (General Medicine Division,
NEMC): You mentioned that the decrease in blood pressure
caused by converting enzyme inhibition is not accompanied by
a reflex tachycardia. What are your views on the reason for this
phenomenon?
DR. ZUSMAN: Although there is limited information on this
issue, evidence indicates that captopril potentiates arterial
baroreflexes, and thus prevents a reflex tachycardia after blood
pressure reduction [107].
DR. COHEN: Steroid hormones are known to inhibit phospho-
lipase activity and thereby diminish prostaglandin production.
Is there any evidence suggesting that the hypertensive effect of
steroids might relate to this action?
DR. ZUSMAN: One of the problems with ascribing a homeo-
static role for prostaglandins in the regulation of blood pressure
is that despite the large number of patients who take nonsteroid-
al antiinflammatory drugs, blood pressure rises in only the
occasional patient. I think a similar relationship is true for
patients who receive steroids. I doubt that the increase in blood
pressure in patients receiving steroid hormones is related to
prostaglandin inhibition; hypertension in these patients proba-
bly develops because of increased sensitivity to vasoconstrictor
hormones, increased plasma renin activity, and/or an increase
in intravascular volume.
DR. HARRINGTON: Has verapamil been used to treat high
blood pressure in the unusual patient with indomethacin-in-
duced hypertension? What would you predict would happen if
verapamil were used, and by what mechanism might it act?
DR. ZUSMAN: I don't know of any patients treated with
verapamil in that setting. It is possible that in hypertensive
patients verapamil produces vasodilation and reduces blood
pressure via blockade of the voltage-dependent calcium chan-
nels and the resultant vascular smooth muscle relaxation [108].
DR. ANDREW LEVEY (Division of Nephrology, NEMC): In-
vitro studies with captopril analogues having no su1flydryI
group inhibit converting enzyme and do not increase prosta-
glandin synthesis. Are these agents effective in lowering blood
pressure in non-renin—dependent hypertension? If so, doesn't
this suggest that at least part of the antihypertensive effect of
captopnl under these circumstances is simply the result of
converting enzyme inhibition?
DR. ZUSMAN: Both captopril and MK-421, the non-sulihy-
dryl—containing converting enzyme inhibitor, lower the blood
pressure of the spontaneously hypertensive rat [109]; this
finding suggests that renin does play an important role in the
pathogenesis of this model of hypertension. Unlike captopril,
MK-421 does not lower the blood pressure of rats with DOCA-
salt hypertension [109] or rats made hypertensive by the
prolonged intravenous infusion of angiotensin II [110]. These
findings, once again, suggest a non-renin—mediated antihyper-
tensive activity of captopril, which I believe is due to the
stimulation of prostaglandin biosynthesis; this activity is not
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shared by the other, non-sulfhydryl—containing, converting
enzyme inhibitors.
Again, one way in which to study the renin- and non-renin—
mediated effects of these compounds would be to administer the
renin-speciflc antibody and give one or the other converting
enzyme inhibitor, or give them sequentially and see whether
you could elicit a greater maximum blood pressure fall with one
than with the other.
DR. LEVEY: Has the effect of these agents on bradykinin been
studied?
DR. ZUSMAN: The investigational compound MK-42l has no
consistent effect on plasma bradykinin levels (C. SWEET,
personal communication).
DR. MADIAS: What is the mechanism of the suppression of
the initial hyperreninemia during chronic captopril administra-
tion? Also, are there any data suggesting that chronic captopril
treatment might lead to the development of autonomous hyper-
reninemia, that is, hyperreninemia that will be sustained follow-
ing discontinuation of captopril administration?
DR. ZUSMAN: I am not aware of any evidence that autono-
mous hyperreninemia occurs. The drop in plasma renin activity
after the acute increase is, I think, secondary to volume
expansion. Retention of sodium and water frequently occurs
following the administration of vasodilators such as hydral-
azine, prazosin, captopril, or nifedipine. If hypertension recurs
in a patient with suppression of renin activity after chronic
captopril therapy, the patient will become sensitive once again
to the effects of captopril following the administration of a
diuretic. The patient exhibits an acute hyperreninemic response
following initial captopril administration, and blood pressure
drops; thereafter, the patient's intravascular volume increases,
and renin is suppressed by a "volume-sensitive" mechanism;
the administration of a diuretic at this point restores the renin-
dependent mechanism of blood pressure homeostasis, and the
patient's blood pressure decreases because of converting en-
zyme inhibition and increased prostaglandin biosynthesis.
DR. MADIAS: Does captopril change the level of renin
substrate?
DR. ZUSMAN: Yes, the concentration of renin substrate can
fall because of the increase in renin activity and the generation
of angiotensin I [ill].
DR. COHEN: We now have a large array of antihypertensive
drugs available to choose from in planning treatment in an
individual patient. Where do you place captopril in the overall
scheme of things?
DR. ZUSMAN: The concept of step therapy for hypertension is
becoming less rigid as drugs with novel mechanisms of action
are becoming available. The original use of captopril was
limited to the patient with severe or resistant hypertension
because concerns existed about the drug's potential toxicity.
Now that large numbers of patients have received captopril,
however, it has become clear that these risks are minimal. For
example, in the patient with normal renal function and without
collagen vascular disease, the risk of neutropenia associated
with captopril administration is no greater than that associated
with the administration of other antihypertensive medications
[112]. I think captopril should be considered as first-step
therapy in some patients, especially those who have contraindi-
cations to diuretics, those with borderline left-ventricular func-
tion, or those who have had side effects following administra-
Table 2. Costs of commonly used antihypertensive medications
Drug
Total
daily dose
Approximate
cost per month
Hydrochlorothiazide 50 mg $ 1.50
Propranolol
Nadolol
Timolol
160 mg
80 mg
20 mg
11.50
13.00
15.00
Alpha-methyldopa 1000 mg 13.00
Hydralazine
Prazosin
150 mg
4 mg
8.00
11.00
Captopril 50 mg 16.00
K-Lyte
KCI Elixir
25 mEq
20 mEq
12.00
2.50
Average costs are for the Boston metropolitan area. Costs may vary
considerably in different locations.
tion of beta blockers or centrally acting sympatholytic agents.
Now that it has been demonstrated that captopril can be used
on a regimen of twice-daily doses [106], it is reasonable for us to
consider its use in patients who lead active lives. With this
newly available information, we should not reserve captopril
only for the patient with resistant or severe hypertension.
DR. COHEN: Are you concerned about proteinuria associated
with the use of this agent?
DR. ZUSMAN: The incidence of proteinuria is most marked in
patients with preexisting renal failure and in those receiving
doses greater than 150 mg/day. In patients with normal renal
function who receive less than 150 mg/day, the incidence of
proteinuria is 0.2%; the incidence rises to 1% in patients
receiving more than 150 mg/day. In patients with a history of
renal disease, the incidence increases to 1% and 3.5% in
patients receiving less than or greater than ISO mg/day, respec-
tively [1131.
DR. HARRINGTON: Could you comment on the use of capto-
pril in pregnancy? What happens to uterine blood flow in
experimental animals given converting enzyme inhibitors?
DR. ZUSMAN: The administration of captopril to pregnant
rabbits significantly reduced systemic blood pressure and uter-
ine blood flow and was associated with a 90% fetal mortality
rate [114]. Pregnancy is one of the few absolute contraindica-
tions to captopril administration.
DR. COHEN: What about the cost of captopril?
DR. ZUSMAN: Table 2 illustrates the costs of typical doses of
antihypertensive medications for patients with mild to moderate
hypertension. In patients responding to low doses of a beta
blocker, sympatholytic, vasodilator, or converting enzyme in-
hibitor, the costs are comparable. Hydrochlorothiazide, 50 mg
daily, is considerably less expensive if a potassium supplement
is not required. In patients receiving double- or triple-drug
therapy, the costs, of course, can exceed the costs of low-dose
captopril therapy.
DR. LEVEY: What is a reasonable dose of captopril for
patients with renal insufficiency who are on dialysis?
DR. ZUSMAN: Captopril is excreted by the kidneys. Therefore
the interval between doses should be increased in patients with
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progressively severe renal failure; in patients without functional
renal tissue the interval between doses can be as long as 120
hours [115].
DR. LEVEY: Plasma renin activity and urinary prostaglandin
E2 excretion are both increased in numerous clinical circum-
stances, including congestive heart failure, volume depletion,
and cirrhosis. What is the link between them? For example, do
you think that the rise in angiotensin II levels stimulates renal
prostaglandin synthesis?
DR. ZUSMAN: Multiple factors affect urinary prostaglandin
excretion; these include plasma potassium concentration, an-
giotensin II, antidiuretic hormone, and urine flow rate [116].
The disorders you have mentioned are all associated with an
increase in plasma angiotensin II and vasopressin concentra-
tion, which may be the unifying factors. In patients with the
hepatorenal syndrome, however, urinary thromboxane, and not
PGE2 excretion, is increased; yet plasma renin activity is high
in these patients too [117]. A unifying hypothesis for the control
of urinary prostaglandin excretion is not yet available.
DR. HARRINGTON: You mentioned that captopril increases
prostaglandin synthesis through an increase in arachidonic acid
release. Why does it selectively increase the vasodilatory
prostaglandins?
DR. ZUSMAN: In renomedullary interstitial cells and vascular
endothelial cells one finds a single predominant prostaglandin
product: PGE, in the kidney and PGI2 in endothelium. The
studies of the isolated renal glomeruli are hard to explain. Galler
and coworkers reported the selective increased synthesis of the
vasodilator prostaglandins, PGE2 and PG!,. Their results sug-
gest that compartmentalization of prostacyclin synthetase and
of the endoperoxide isomerase and peroxidase leads to in-
creased PGE2 and PGI2 biosynthesis only [88]. The increased
arachidonic acid released after incubation with captopril would
have to be directed toward these compartmentalized enzymes
selectively. I can think of no other explanation for this
phenomenon.
DR. MADIAs: What is your assessment of the role of the
decreased levels of aldosterone in the hypotensive effect of
converting enzyme inhibition? Somewhat conflicting results
have been obtained in the dog [118, 119].
DR. ZUSMAN: The restoration of normal blood pressure levels
by aldosterone administration in animals treated with captopril
is inconsistent with our understanding of the role of aldosterone
in blood pressure control. The results of Hall et al [118] directly
contradict those of McCaa and colleagues [40] but are more
consistent with the primary role of angiotensin H rather than
aldosterone in blood pressure control of sodium-depleted ani-
mals. In sodium-replete animals, even large doses of steroids
fail to prevent the hypotensive response to captopril; this
response clearly is related to prostaglandin stimulation by
captopril [1191.
DR. VINCENT CANZANELLO (Renal Fellow, Division of
Nephrology, NEMC): Hyperkalemia has been reported in pa-
tients with decreased glomerular filtration rates who are receiv-
ing captopril. Has hyperkalemia occurred in patients with
essential hypertension and normal renal function, particularly
when captopril is used without a potassium-sparing diuretic?
DR. ZUSMAN: Abnormalities of serum potassium concentra-
tion are rare in patients who are receiving captopril with or
without diuretics unless the patient is simultaneously receiving
a potassium supplement or a potassium-sparing diuretic. The
simultaneous use of a converting enzyme inhibitor (which
reduces plasma aldosterone concentration and thereby reduces
potassium excretion) and a potassium-sparing agent—amilor-
ide, spironolactone, or triamterene—can result in clinically
significant hyperkalemia even in a patient with normal renal
function. In patients receiving captopril, these agents should be
used with care and close supervision.
Reprint requests to Dr. R. Zusman, Hypertension Division, Cardiac
Unit, Massachusetts General Hospital. 15 Parkman Street, Boston,
Massachusetts 02/14
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